S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcino...
S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma
About this item
Full title
Author / Creator
El-Khoueiry, A B , Rankin, C , Siegel, A B , Iqbal, S , Gong, I-Y , Micetich, K C , Kayaleh, O R , Lenz, H-J and Blanke, C D
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Background:
Gallbladder cancers and cholangiocarcinomas make up a heterogenous group of tumours with a poor prognosis in advanced stages. On the basis of evidence of dysregulation of the epidermal growth factor receptor, vascular endothelial growth factor and mitogen-activated protein kinase pathways in biliary cancers, we performed a phase 2 tr...
Alternative Titles
Full title
S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3929880
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3929880
Other Identifiers
ISSN
0007-0920
E-ISSN
1532-1827
DOI
10.1038/bjc.2013.801
